ID
stringlengths 11
11
| tags
stringlengths 10
777
| text
stringlengths 2
1.5k
| dataset_num
int64 1
3
| tokens
sequence | ner_tags
sequence |
|---|---|---|---|---|---|
NCT00338377 | 27:46:chronic_disease,166:179:treatment,223:235:treatment,236:249:treatment | Presence of a significant psychiatric disease, which in the opinion of the principal investigator or his designee, would prevent adequate informed consent or render immunotherapy unsafe or contraindicated. (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria) | 3 | [
"Presence",
"of",
"a",
"significant",
"psychiatric",
"disease",
",",
"which",
"in",
"the",
"opinion",
"of",
"the",
"principal",
"investigator",
"or",
"his",
"designee",
",",
"would",
"prevent",
"adequate",
"informed",
"consent",
"or",
"render",
"immunotherapy",
"unsafe",
"or",
"contraindicated",
".",
"(",
"Turnstile",
"II",
"-",
"Chemotherapy/Cell",
"Infusion",
"Exclusion",
"Criteria",
")"
] | [
0,
0,
0,
0,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
0,
0
] |
NCT00338377 | 82:94:treatment,125:137:treatment,138:151:treatment | will be excluded because of the potentially dangerous effects of the preparative chemotherapy on the fetus. (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria) | 3 | [
"will",
"be",
"excluded",
"because",
"of",
"the",
"potentially",
"dangerous",
"effects",
"of",
"the",
"preparative",
"chemotherapy",
"on",
"the",
"fetus",
".",
"(",
"Turnstile",
"II",
"-",
"Chemotherapy/Cell",
"Infusion",
"Exclusion",
"Criteria",
")"
] | [
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
0,
0
] |
NCT00258427 | 1:4:chronic_disease,19:25:chronic_disease,27:33:chronic_disease,44:61:chronic_disease | HIV-NAT negative, HTLV-1, HTLV-2 negative, Hepatitis B and C negative | 3 | [
"HIV-NAT",
"negative",
",",
"HTLV-1",
",",
"HTLV-2",
"negative",
",",
"Hepatitis",
"B",
"and",
"C",
"negative"
] | [
2,
0,
0,
2,
0,
2,
0,
0,
2,
2,
2,
2,
0
] |
NCT00147056 | 1:23:treatment,28:39:treatment,66:76:chronic_disease,85:131:treatment,133:140:treatment | Anti-coagulant therapy, on medications known to increase risk of hemorrhage, (e.g.: non-steroidal anti-inflammatory drugs (NSAIDs), statins | 3 | [
"Anti-coagulant",
"therapy",
",",
"on",
"medications",
"known",
"to",
"increase",
"risk",
"of",
"hemorrhage",
",",
"(",
"e.g",
".",
":",
"non-steroidal",
"anti-inflammatory",
"drugs",
"(",
"NSAIDs",
")",
",",
"statins"
] | [
1,
1,
0,
0,
1,
0,
0,
0,
0,
0,
2,
0,
0,
0,
0,
0,
1,
1,
1,
1,
0,
0,
0,
1
] |
NCT00147056 | 16:39:treatment,47:56:treatment,77:83:treatment | who are not on anti seizure medication (e.g., Phenytoin 100 mg PO t.i.d. or Keppra 500 mg po bid) before the procedure | 3 | [
"who",
"are",
"not",
"on",
"anti",
"seizure",
"medication",
"(",
"e.g.",
",",
"Phenytoin",
"100",
"mg",
"PO",
"t.i.d",
".",
"or",
"Keppra",
"500",
"mg",
"po",
"bid",
")",
"before",
"the",
"procedure"
] | [
0,
0,
0,
0,
1,
1,
1,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT00107289 | 15:20:chronic_disease,22:29:chronic_disease,31:38:chronic_disease,40:49:chronic_disease,51:67:chronic_disease,72:91:chronic_disease, | Specifically, renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade 2 or less | 3 | [
"Specifically",
",",
"renal",
",",
"cardiac",
",",
"hepatic",
",",
"pulmonary",
",",
"gastrointestinal",
"and",
"neurologic",
"toxicity",
"should",
"all",
"be",
"grade",
"2",
"or",
"less"
] | [
0,
0,
2,
0,
2,
0,
2,
0,
2,
0,
2,
0,
2,
2,
0,
0,
0,
0,
0,
0,
0
] |
NCT00085982 | 34:58:chronic_disease,75:101:chronic_disease,127:143:chronic_disease,148:160:chronic_disease | Also, in our experience with the Type A insulin resistant patients, their initial insulin resistance is manifested as extreme hyperinsulinemia and hypoglycemia in the younger patients | 3 | [
"Also",
",",
"in",
"our",
"experience",
"with",
"the",
"Type",
"A",
"insulin",
"resistant",
"patients",
",",
"their",
"initial",
"insulin",
"resistance",
"is",
"manifested",
"as",
"extreme",
"hyperinsulinemia",
"and",
"hypoglycemia",
"in",
"the",
"younger",
"patients"
] | [
0,
0,
0,
0,
0,
0,
0,
2,
2,
2,
2,
0,
0,
0,
2,
2,
2,
0,
0,
0,
0,
2,
0,
2,
0,
0,
0,
0
] |
NCT00044304 | 33:36:treatment,40:54:treatment,79:90:treatment | Evidence of B cell clonality by PCR or flow cytometry (exclusion criteria for ruxolitinib only) | 3 | [
"Evidence",
"of",
"B",
"cell",
"clonality",
"by",
"PCR",
"or",
"flow",
"cytometry",
"(",
"exclusion",
"criteria",
"for",
"ruxolitinib",
"only",
")"
] | [
0,
0,
0,
0,
0,
0,
1,
0,
1,
1,
0,
0,
0,
0,
1,
0,
0
] |
NCT00001208 | 53:61:chronic_disease,63:79:chronic_disease,81:94:chronic_disease,96:102:chronic_disease,104:123:chronic_disease,125:129:chronic_disease,131:148:chronic_disease,150:173:chronic_disease,175:193:chronic_disease,195:205:chronic_disease | Applicable disorders include but are not limited to dystonia, hemifacial spasm, blepharospasm, tremor, spasmodic dysphonia, tics, vocal fold tremor, oral lingual dyskinesia, tardive dyskinesia, spasticity, and spasmodic dysphonia | 3 | [
"Applicable",
"disorders",
"include",
"but",
"are",
"not",
"limited",
"to",
"dystonia",
",",
"hemifacial",
"spasm",
",",
"blepharospasm",
",",
"tremor",
",",
"spasmodic",
"dysphonia",
",",
"tics",
",",
"vocal",
"fold",
"tremor",
",",
"oral",
"lingual",
"dyskinesia",
",",
"tardive",
"dyskinesia",
",",
"spasticity",
",",
"and",
"spasmodic",
"dysphonia"
] | [
0,
0,
0,
0,
0,
0,
0,
0,
2,
0,
2,
2,
0,
2,
0,
2,
0,
2,
2,
0,
2,
0,
2,
2,
2,
0,
2,
2,
2,
0,
2,
2,
0,
2,
0,
0,
0,
0
] |